Cytiva Cell and Gene Webinars and Podcasts
- Unpacking pDNA processes: Capacity, complexity, and cutting-edge solutions 11/20/2025
- The future is now: are you keeping pace with oligo synthesis optimization? 11/18/2025
- Enhancing viral vector sterile filtration: process efficiency and GMP alignment 11/4/2025
-
CRISPR Meets LNPs: A New Era In Cell And Gene Therapies
7/8/2025
Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.
-
Flexibility To Meet Your Process Needs
6/11/2025
Explore a platform that adapts to your evolving workflow through real-world examples of how its flexibility supports diverse inputs, applications, and parameters to ensure consistency, scalability, and efficiency.
-
Prevent Batch Failures Before They Happen
6/11/2025
Discover a platform that reduces operator errors and batch failures through automation, real-time monitoring, and intelligent design to ensure greater process reliability and consistent outcomes in your workflow.
-
Easy Integration Of A New Manufacturing Platform
6/11/2025
Easily integrate an innovative platform into your manufacturing process with seamless onboarding, regulatory support, and expert guidance that is designed to help you confidently adopt good manufacturing practices.
-
Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery
6/3/2025
Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.
-
Elevating AAV Manufacturing WithTailored Cell Lines
9/19/2024
Skillfully crafted cell lines can substantially enhance vector purity and yield. Watch to explore a portfolio of engineered cell lines and their potential to transform the landscape of AAV production.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?